ZYLOXTB (02190) plans to acquire 49% of Optimed Holding for 18.375 million euros as a key milestone in entering the European and global markets.

ZYLOXTB (02190) issued an announcement on January 16, 2026, stating that the company (as the buyer) has entered into a sale and purchase agreement with E-Med Solutions (as the seller). According to the agreement, the buyer agrees to acquire 49% equity of the target company, Optimed Holding GmbH, for a total consideration of approximately 18.375 million euros. The buyer also obtained an option, at its discretion, to acquire the remaining equity of the target company from other shareholders. Following the completion of the acquisition, the target company will not become a subsidiary of the company, and the financial performance of the target company will not be incorporated into the company's financial statements. The target group is primarily engaged in the development, manufacturing, and distribution of medical technology products, instruments, and solutions. Within the target group, the wholly-owned subsidiary of the target company, Optimed Medizinische Instrumente GmbH, is its main operating subsidiary. Headquartered in Ettersheim, Germany, the company is dedicated to the research, manufacturing, and global distribution of high-quality medical products for minimally invasive vascular and urological surgery instruments. Optimed has the most complete product range in the peripheral vascular stent market, including devices for iliac veins, iliac artery bifurcation, inferior vena cava, and aortic applications. The board believes that the acquisition will bring the following benefits to the company: 1. Marks an important milestone in the company's long-term commitment to global expansion. The acquisition represents a key milestone in the company's commitment to expanding into the European and global markets. By integrating these assets, the company will accelerate its international strategic deployment, diversify its product portfolio, expand its global distribution network, significantly enhance the company's competitive position and influence on the international stage. 2. Building an integrated global commercial platform to accelerate the global application of innovative vascular solutions. The integration strength of the company and Optimed sales networks will accelerate the global application of innovative vascular solutions. With a broader and more diverse product portfolio, the company has a competitive advantage in expanding markets beyond mainland China. A key element of this strategy is to leverage Optimed's deep collaboration with European medical experts to accelerate clinical processes and promote successful product launches. 3. Achieving significant manufacturing and operational synergies between Germany and China. The transaction will achieve significant manufacturing and operational synergies between Germany and China. By integrating advanced production capabilities, the company will continue to enhance overall product quality and operational efficiency. The company will continue to leverage the strong brand reputation of the target company in Europe while strategically expanding its production capacity in Germany to ensure a stable, reliable, and efficient supply for European and other key international markets. 4. Fully unleash the group's efficient research and development capabilities. The company's integrated global commercial platform will empower and fully unleash the group's efficient research and development capabilities. By further expanding the company's innovation globally beyond the domestic market, the company is committed to providing cutting-edge, high-quality medical solutions to patients and healthcare professionals worldwide. Following the completion of the acquisition, the company and the target company will fully integrate their commercial platforms, including sales and marketing networks, market promotion capabilities, and customer service infrastructure. The target company will serve as the exclusive distributor of all vascular products of the company in markets outside mainland China. Rdiger Hausherr will continue to serve as the CEO of Optimed and report to Dr. Zhao Zhongbo, Chairman and CEO of the company. This strategic arrangement will significantly enhance and accelerate the company's international sales capabilities and global expansion pace.